




# ELIGARD<sup>®</sup>

leuprorelin acetate



The only subcutaneous ADT injection available in 4 dosing options<sup>1</sup>



**1 month | 7.5 mg**  
5 repeats  
12 injections per year

**3 month | 22.5 mg**  
1 repeat  
4 injections per year

**4 month | 30 mg**  
1 repeat  
3 injections per year

**6 month | 45 mg**  
0 repeats  
2 injections per year



### EFFICACY<sup>1,2</sup>

Mean serum testosterone suppression to **>0.44 nmol/L across all doses**



### SUBCUTANEOUS ADMINISTRATION<sup>1</sup>

Short needle length (1.59 cm) and small injection volume (<0.5 mL)



### FLEXIBLE DOSING OPTIONS<sup>1</sup>

1, 3, 4 and 6 months

**Abbreviation:** ADT = androgen deprivation therapy.

**PBS Information: Restricted Benefit.** Locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate.

Please review the Product Information before prescribing. Product Information can be accessed via [www.mundipharma.com.au/products](http://www.mundipharma.com.au/products) or via the QR code.

Adverse events should be reported. Reporting forms and information can be found at <https://aems.tga.gov.au/>. Adverse events should also be reported to [drugsafety@mundipharma.com.au](mailto:drugsafety@mundipharma.com.au)

**Reference:** 1. ELIGARD<sup>®</sup> Approved Product Information, Jul 2022. 2. Shore ND, *et al.* BJU Int 2017;119(2):239-44.

